MIV Therapeutics' CEO Mark Landy Joins Distinguished Leaders Selected to This Year's PharmaVOICE 100

2008-07-29 23:38:04 -

- Dr. Mark Landy, President and Chief Executive Officer of Atlanta, GA-based MIV Therapeutics, Inc. (OTCBB: MIVT, Frankfurt: MIV, www.mivtherapeutics.com), a leading developer of next-generation coatings and advanced drug-delivery systems for cardiovascular stents and other implantable medical devices, was named to the "PharmaVOICE 100," an annual list of individuals who are having a remarkable influence on the life sciences industry.

A former financial analyst and portfolio manager, Dr. Landy is using his past experiences to reach his goal: widening the often-troubled stent market by building an advanced drug-delivery system for cardiac stents and implantable medical devices. Dr. Landy's nomination and ultimate selection derived from his tenacity in distinguishing himself in the medical device sector. "In the office, he motivates his staff by always striving to treat others fairly and give them the latitude to explore the boundaries of their professional curiosity," according to the editors of PharmaVOICE.

This year's distinguished list of one hundred leaders was selected by PharmaVOICE readers, who nominated individuals in the industry that had inspired and motivated them. Thousands of readers submitted nominations; ultimately, the PharmaVOICE 100 was selected based on these recommendations, the number of nominations received, and other factors, such as community and philanthropic activities.

"To be considered one of the hundred people this year who serve as an inspiration to the industry is truly an honor," said Dr. Landy. "I am thankful to both my peers and PharmaVOICE for this kind tribute. This commendation has given me even more encouragement to continue to lead MIV in the positive direction in which we are heading."

PharmaVOICE divided the honorees into different categories that best capture their individual skill sets and expertise, with Dr. Landy positioned in the "Commanders and Chiefs" category. As defined by PharmaVOICE, these entrepreneurs are redefining the life-sciences industry through innovative approaches to improving technologies, processes, services, and, ultimately, patient care.

The article can be seen on www.pharmavoice.com/100 or you can request a copy by e-mailing Janet Vasquez at jvasquez@investorrelationsgroup.com.

About MIV Therapeutics

MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents, as well as for a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. This coating platform is derived from hydroxyapatite (HAp), an organic material that has demonstrated excellent in vivo safety and biocompatibility. Hydroxyapatite is a porous material that makes up the bone mineral and matrix of teeth, and is widely used today as a bone substitute material and for coatings on implantable fixation devices in orthopedic, dental and other applications. The Company's novel polymer-free drug-eluting technologies based on HAp could also provide an attractive alternative to current polymer-based drug-eluting coatings on the stent market, which have been associated with undesirable effects. The Company's drug-eluting coatings are additionally designed to suit a broad range of implantable medical devices that could benefit from highly customizable drug release profiles. MIV Therapeutics has a Collaborative Research Agreement with the University of British Columbia and has received a government grant for its research program on the "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents," under the National Research Council-Industrial Research Assistance Program. Under this sponsorship, the Company is expected to complete its drug-eluting research and development program and to reach product commercialization. MIV's intellectual property portfolio includes patents held by the University of British Columbia and exclusively licensed to MIV. Key patent applications filed simultaneously in various countries around the world further protect the commercial exclusivity of MIV's inventions in the global marketplace. For more information, please visit www.mivtherapeutics.com.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. All statements that discuss expectations and projections with respect to future matters including, without limitation, statements relating to the safety and efficacy of the Company's product and the ability of the Company's product to rejuvenate the stent market are forward-looking statements. Such statements are indicated by words or phrases such as "proposed," "expected," "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." Such statements include but are not limited to that the split is part of a series of strategic moves to strengthen the Company's financial position for future growth and development. These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties including, without limitation, market acceptance of the Company's product, the ability of the Company to raise sufficient funding and to continue to develop its various business interests as presently contemplated, and other factors identified in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's annual report on Form 10-K for the year ended May 31, 2007 and Forms 10-Q. The Company expressly disclaims any obligation to update publicly or otherwise revise these statements, whether as a result of new information, future events or otherwise, except to the extent required by law.

MIV Therapeutics, Inc.
Investors:
Anthony L. Huston, 604-301-9545 ext. 14
Director of Investor Relations
ahuston@mivtherapeutics.com
investor@mivtherapeutics.com
or
The Investor Relations Group
Investor Relations:
Rachel Colgate / Adam Holdsworth / Erica Ruderman
212-825-3210
or
Media Relations:
Laura Colontrelle / Janet Vasquez
212-825-3210